Vetoquinol - Public Comps and Valuation Multiples

Vetoquinol Overview

About Vetoquinol

Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.

Founded

1933

HQ

Employees

2.1K+

Website

vetoquinol.com

Sectors

Pet Care
Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $627M

LTM EBITDA $123M

EV

$883M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Vetoquinol Financials

As of September 2025, Vetoquinol reported last 12-month revenue of $627M and EBITDA of $123M.

In the same period, Vetoquinol achieved $77.3M in LTM net income.

See Vetoquinol valuation multiples based on analyst estimates

Vetoquinol P&L

In the most recent fiscal year, Vetoquinol reported revenue of $624M and EBITDA of $132M.

Vetoquinol expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Vetoquinol valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$627M	XXX	$624M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$448M	XXX	XXX	XXX
Gross Margin	n/a	XXX	72%	XXX	XXX	XXX
EBITDA	$123M	XXX	$132M	XXX	XXX	XXX
EBITDA Margin	20%	XXX	21%	XXX	XXX	XXX
EBIT	$94.0M	XXX	$88.2M	XXX	XXX	XXX
EBIT Margin	15%	XXX	14%	XXX	XXX	XXX
Net Profit	$77.3M	XXX	$67.9M	XXX	XXX	XXX
Net Margin	12%	XXX	11%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Vetoquinol including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $627M. EBITDA for the last twelve months was $123M. In the most recent fiscal year, Vetoquinol achieved $624M in revenue and $132M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$627M	Analyst estimates available to subscribers	$624M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$448M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	71.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$123M	Analyst estimates available to subscribers	$132M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	19.6% EBITDA margin	Analyst estimates available to subscribers	21.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$94.0M	Analyst estimates available to subscribers	$88.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	15.0% EBIT margin	Analyst estimates available to subscribers	14.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$77.3M	Analyst estimates available to subscribers	$67.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	12.3% net profit margin	Analyst estimates available to subscribers	10.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Vetoquinol

This financial data table provides comprehensive performance metrics for Vetoquinol, a company based in France. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Vetoquinol generated $627M in revenue over the last twelve months.
The company achieved $123M in EBITDA over the last twelve months.
Net income over the last twelve months reached $77.3M.

Fiscal Year Performance

In the most recent fiscal year, Vetoquinol reported $624M in total revenue.
Fiscal year EBITDA was $132M.
The company maintained a gross profit margin of 71.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 21.2%.
Net profit margin reached 10.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Vetoquinol. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Vetoquinol Stock Performance

Vetoquinol has current market cap of EUR 930M (or $1.1B), and EV of EUR 763M (or $883M).

Market Cap Evolution

Vetoquinol Stock Data

As of October 17, 2025, Vetoquinol's stock price is EUR 79 (or $91).

See Vetoquinol trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$883M	$1.1B	XXX	XXX	XXX	XXX	$5.93

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Vetoquinol Valuation Multiples

Vetoquinol's trades at 1.4x EV/Revenue multiple, and 6.7x EV/EBITDA.

See valuation multiples for Vetoquinol and 15K+ public comps

Vetoquinol Financial Valuation Multiples

As of October 17, 2025, Vetoquinol has market cap of $1.1B and EV of $883M.

Equity research analysts estimate Vetoquinol's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vetoquinol has a P/E ratio of 13.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.1B	XXX	$1.1B	XXX	XXX	XXX
EV (current)	$883M	XXX	$883M	XXX	XXX	XXX
EV/Revenue	1.4x	XXX	1.4x	XXX	XXX	XXX
EV/EBITDA	7.2x	XXX	6.7x	XXX	XXX	XXX
EV/EBIT	9.4x	XXX	10.0x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	13.9x	XXX	15.8x	XXX	XXX	XXX
EV/FCF	12.1x	XXX	11.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vetoquinol Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Vetoquinol Margins & Growth Rates

Vetoquinol's last 12 month revenue growth is 3%

Vetoquinol's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Vetoquinol's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vetoquinol's rule of X is 27% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Vetoquinol and other 15K+ public comps

Vetoquinol Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	3%	XXX	2%	XXX	XXX	XXX
EBITDA Margin	20%	XXX	21%	XXX	XXX	XXX
EBITDA Growth	4%	XXX	-2%	XXX	XXX	XXX
Rule of 40	24%	XXX	24%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	27%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	58%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial